Vivani Medical (VANI) Liabilities and Shareholders Equity (2014 - 2026)
Vivani Medical (VANI) posted quarterly Liabilities and Shareholders Equity of $42.4 million for Q1 2026, up 5950.43% year-over-year from $700000.0 in Q1 2025, and up 7.51% quarter-over-quarter from $39.4 million in Q4 2025.
Vivani Medical (VANI) Liabilities and Shareholders Equity (2014 - 2026) Analysis & Trends
Vivani Medical's Liabilities and Shareholders Equity history runs 13 years deep, the most recent figure standing at $42.4 million for Q1 2026.
- In Q1 2026, Liabilities and Shareholders Equity rose 5950.43% year-over-year to $42.4 million; the TTM figure through Mar 2026 stood at $135.7 million (up 1.74% YoY), while the FY2025 annual figure was $39.4 million, down 5.22% from the prior year.
- Liabilities and Shareholders Equity for Q1 2026 stood at $42.4 million, up from $39.4 million in the prior quarter.
- The five-year high for Liabilities and Shareholders Equity was $68.5 million in Q1 2022, with the low at $700000.0 in Q1 2025.
- The 5-year median for Liabilities and Shareholders Equity is $45.8 million (2023), against an average of $45.2 million.
- The sharpest annual moves came in 2025 and 2026: Liabilities and Shareholders Equity slumped 98.7% in 2025, then soared 5950.43% in 2026.
- Vivani Medical's Liabilities and Shareholders Equity stood at $51.1 million in 2022, then decreased by 10.43% to $45.8 million in 2023, then declined by 9.25% to $41.6 million in 2024, then dropped by 5.22% to $39.4 million in 2025, then advanced by 7.51% to $42.4 million in 2026.
- Business Quant data shows VANI's Liabilities and Shareholders Equity at $42.4 million in Q1 2026, $39.4 million in Q4 2025, and $25.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 10.96 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 9.18 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 5.56 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 25.60 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 2.10 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.82 Bn |
| 10 | Vivani Medical | 120.18 Mn | 100.29 Mn | - | 41.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 41.64 Mn |
| Mar 31, 2026 | 42.35 Mn |
| Dec 31, 2025 | 39.39 Mn |
| Sep 30, 2025 | 25.05 Mn |
| Jun 30, 2025 | 28.91 Mn |
| Mar 31, 2025 | 700,000.00 |
| Dec 31, 2024 | 41.56 Mn |
| Sep 30, 2024 | 42.90 Mn |
| Jun 30, 2024 | 48.22 Mn |
| Mar 31, 2024 | 53.79 Mn |
| Dec 31, 2023 | 45.80 Mn |
| Sep 30, 2023 | 53.32 Mn |
| Jun 30, 2023 | 59.61 Mn |
| Mar 31, 2023 | 44.58 Mn |
| Dec 31, 2022 | 51.13 Mn |
| Sep 30, 2022 | 57.02 Mn |
| Jun 30, 2022 | 65.65 Mn |
| Mar 31, 2022 | 68.54 Mn |
| Dec 31, 2021 | 5.45 Mn |
| Sep 30, 2021 | 73.63 Mn |